Table 1.

Baseline patient demographics

Patient demographicsPhases I and II (n = 50)
Age, years, median (range)63 (39–85)
Sex, male/female (%)20 (40)/30 (60)
ECOG performance status, n (%)
 06 (12)
 143 (86)
 21 (2)
Prior lines of SCLC therapy, n (%)
 123 (46)
 217 (34)
 34 (8)
 >36 (12)
 Median (range)2 (1–7)
Chemotherapy-free interval
 ≥ 90 days (“platinum sensitive”; %)36 (72)
 < 90 days (“platinum resistant”; %)14 (28)
 Baseline brain metastases present (%)20 (40)
 Treated8 (16)
 Untreated12 (24)